Dateline City:
WHITEHOUSE STATION, N.J.
2013 Third-Quarter Non-GAAP EPS of $0.92, Excluding Certain Items; GAAP EPS of $0.38
Worldwide Sales were $11.0 Billion, a Decrease of 4 Percent Reflecting the Unfavorable Impact of Patent Expiries and a 2 Percent Negative Impact from Foreign Exchange
Strong Growth in Vaccines and Immunology as well as ISENTRESS
Breakthrough Therapy Designation Granted for MK-5172/MK-8742, in Development for the Treatment of Chronic Hepatitis C Virus Infection; V503, Mercks Investigational 9-valent HPV Vaccine has Completed Pivotal Phase III Study, on Track for 2013 Submission
Narrows Full-Year Non-GAAP EPS Target to $3.48 to $3.52; GAAP EPS Target to $1.61 to $1.79
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced financial results for the third quarter of 2013.
$ in millions, except EPS amounts
ThirdQuarter2013
ThirdQuarter2012
Language:
English
Contact:
MerckMedia Contacts:Kelley Dougherty, 908-423-4291Steven Cragle, 908-423-3461orInvestor Contacts:Carol Ferguson, 908-423-4465Joe Romanelli, 908-423-5185
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more